LYRA Stock Price, Lyra Therapeutics Inc Quote, Chart

Market Summary

USD0.38+0.01

Delayed

2.70%

LYRA Stock Price

View Fullscreen

LYRA RSI Chart

LYRA Valuation

Market Cap

23.2M

Price/Earnings (Trailing)

-0.34

Price/Sales (Trailing)

13.79

EV/EBITDA

-0.11

Price/Free Cashflow

-0.32

LYRA Price/Sales (Trailing)

LYRA Profitability

EBT Margin

-4096.31%

Return on Equity

-88.87%

Return on Assets

-48.67%

Free Cashflow Yield

-315.37%

LYRA Fundamentals

LYRA Revenue

Revenue (TTM)

1.7M

Rev. Growth (Yr)

29.76%

Rev. Growth (Qtr)

264.38%

LYRA Earnings

Earnings (TTM)

-68.9M

Earnings Growth (Yr)

-38.12%

Earnings Growth (Qtr)

-48.14%

Breaking Down LYRA Revenue

Last 7 days

2.7%

Last 30 days

-93.0%

Last 90 days

-92.4%

Trailing 12 Months

-86.0%

How does LYRA drawdown profile look like?

LYRA Financial Health

Current Ratio

4.78

LYRA Investor Care

Shares Dilution (1Y)

91.49%

Diluted EPS (TTM)

-1.19

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.7M	0	0	0
2023	1.3M	1.2M	1.4M	1.6M
2022	554.5K	824.0K	1.1M	1.4M
2021	0	0	0	285.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Lyra Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 18, 2024	waksal harlan	acquired	-	-	275,000	executive chair
Nov 10, 2023	waksal harlan	bought	74,095	2.9638	25,000	executive chair
May 31, 2023	nbvm gp, llc	bought	4,387,160	2.43	1,805,420	-
May 31, 2023	perceptive advisors llc	bought	9,000,000	2.4925	3,610,830	-
May 31, 2023	anderson edward t	bought	4,387,160	2.43	1,805,420	-
Jan 31, 2023	richard robert e.	acquired	-	-	30,000	svp, technical operations
Jan 31, 2023	noyes corinne	acquired	-	-	36,667	see remarks
Jun 10, 2022	merrifield c ann	bought	20,200	5.05	4,000	-
May 16, 2022	merrifield c ann	bought	1,640	5.00	328	-
May 13, 2022	merrifield c ann	bought	16,845	4.813	3,500	-

Which funds bought or sold LYRA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Ikarian Capital, LLC	reduced	-15.75	506	6,573,480	0.72%
May 16, 2024	COMERICA BANK	unchanged	-	1,136	7,209	-%
May 16, 2024	JANE STREET GROUP, LLC	added	101	570,878	980,913	-%
May 15, 2024	BARCLAYS PLC	unchanged	-	32,000	204,000	-%
May 15, 2024	Royal Bank of Canada	reduced	-80.1	-13,000	4,000	-%
May 15, 2024	Schonfeld Strategic Advisors LLC	added	756	2,003,950	2,222,520	0.01%
May 15, 2024	OCCUDO QUANTITATIVE STRATEGIES LP	new	-	141,940	141,940	0.03%
May 15, 2024	Ally Bridge Group (NY) LLC	new	-	6,243,270	6,243,270	3.47%
May 15, 2024	Tri Locum Partners LP	new	-	6,088,090	6,088,090	2.11%
May 15, 2024	SUPERSTRING CAPITAL MANAGEMENT LP	new	-	903,667	903,667	0.60%

Are Funds Buying or Selling LYRA?

Are funds buying LYRA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LYRA

No. of Funds

Unveiling Lyra Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	pura vida investments, llc	3.06%	1,613,844	SC 13G/A
Feb 14, 2024	venrock healthcare capital partners ii, l.p.	999%	5,553,552	SC 13G/A
Feb 14, 2024	citadel advisors llc	7.9%	6	SC 13G/A
Feb 14, 2024	nantahala capital management, llc	8.9%	4,752,324	SC 13G/A
Feb 14, 2024	point72 asset management, l.p.	5.7%	3e+06	SC 13G/A
Feb 14, 2024	perceptive advisors llc	24.3%	12,757,563	SC 13D/A
Feb 13, 2024	vestal point capital, lp	5.7%	3e+06	SC 13G
Nov 16, 2023	point72 asset management, l.p.	5.4%	3e+06	SC 13G
Aug 25, 2023	samsara biocapital, l.p.	5.6%	2,780,261	SC 13G
Jun 12, 2023	citadel advisors llc	5.8%	6	SC 13G

Recent SEC filings of Lyra Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 30, 2024	10-Q	Quarterly Report
Apr 30, 2024	8-K	Current Report
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 19, 2024	8-K	Current Report
Apr 19, 2024	PRE 14A	PRE 14A
Apr 01, 2024	EFFECT	EFFECT
Mar 28, 2024	CORRESP	CORRESP
Mar 27, 2024	UPLOAD	UPLOAD
Mar 22, 2024	S-8	Employee Benefits Plan

Peers (Alternatives to Lyra Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Lyra Therapeutics Inc News

Latest updates

Lyra Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Revenue	264.4%	532,000	146,000	544,000	458,000	410,000	11,000	359,000	525,000	468,000	-	-
Operating Expenses	44.7%	24,056,000	16,623,000	17,371,000	16,961,000	17,723,000	15,166,000	15,185,000	14,925,000	12,393,000	13,909,000	11,095,000
S&GA Expenses	33.5%	5,818,000	4,357,000	5,003,000	4,570,000	5,127,000	4,399,000	5,137,000	4,132,000	3,888,000	3,567,000	4,018,000
R&D Expenses	48.7%	18,238,000	12,266,000	12,368,000	10,799,000	12,596,000	9,451,000	10,048,000	10,793,000	8,505,000	10,342,000	7,077,000
EBITDA Margin	-2.2%	-40.87	-40.00	-43.06	-48.49	-44.81	-39.73	-38.76	-51.31	-76.25	-149	-
Income Taxes	-17.6%	14,000	17,000	16,000	12,000	14,000	-	-	-	-	-	-
Earnings Before Taxes	-48.2%	-22,438,000	-15,139,000	-15,635,000	-15,606,000	-16,241,000	-14,222,000	-14,766,000	-14,366,000	-11,911,000	-	-
EBT Margin	-1.9%	-40.96	-40.19	-43.36	-49.14	-45.67	-40.55	-39.79	-52.81	-78.47	-152	-
Net Income	-48.1%	-22,452,000	-15,156,000	-15,651,000	-15,618,000	-16,255,000	-14,235,000	-14,766,000	-14,366,000	-11,911,000	-13,617,000	-11,055,000
Net Income Margin	-1.9%	-41.00	-40.23	-43.40	-49.17	-45.69	-40.56	-49.99	-61.83	-85.88	-152	-
Free Cashflow	-24.0%	-24,604,000	-19,845,000	-14,258,000	-14,353,000	-15,895,000	-12,192,000	-10,875,000	-8,484,000	-11,998,000	-12,380,000	-10,831,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																		(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Assets	-0.8%	142	143	121	126	94.00	110	119	130	47.00	55.00	68.00	76.00	73.00	81.00	87.00	93.00	41.00	15.00
Current Assets	-14.7%	89.00	105	105	118	85.00	101	112	122	41.00	48.00	61.00	70.00	67.00	76.00	84.00	89.00	36.00	10.00
Cash Equivalents	-29.3%	16.00	22.00	25.00	54.00	22.00	33.00	110	121	34.00	46.00	58.00	69.00	66.00	75.00	82.00	87.00	35.00	10.00
Net PPE	85.2%	4.00	2.00	1.00	1.00	2.00	2.00	4.00	4.00	4.00	5.00	5.00	4.00	3.00	2.00	1.00	0.00	0.00	0.00
Liabilities	20.4%	64.00	53.00	36.00	27.00	28.00	29.00	26.00	24.00	24.00	21.00	21.00	19.00	5.00	6.00	6.00	6.00	7.00	8.00
Current Liabilities	-4.5%	19.00	20.00	19.00	14.00	14.00	14.00	14.00	11.00	22.00	18.00	18.00	6.00	4.00	5.00	5.00	4.00	5.00	5.00
Shareholder's Equity	-13.3%	78.00	89.00	84.00	99.00	66.00	81.00	93.00	106	23.00	34.00	47.00	57.00	68.00	74.00	81.00	87.00	-	-
Retained Earnings	-7.2%	-333	-311	-296	-280	-264	-248	-234	-219	-205	-193	-179	-168	-157	-149	-142	-136	-131	-127
Additional Paid-In Capital	2.6%	411	401	380	379	331	329	328	326	229	228	227	226	225	224	224	223	5.00	4.00
Shares Outstanding	6.6%	61.00	57.00	50.00	50.00	37.00	32.00	37.00	24.00	13.00	13.00	13.00	13.00	-	-	-	-	-	-
Float	-	-	-	-	143,246	-	-	-	102,993	-	-	-	-	-	-	-	53,323	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-17.8%	-22,455	-19,058	-14,114	-14,282	-15,850	-12,164	-10,846	-8,470	-11,905	-11,297	-10,314	3,381	-7,590	-5,868	-3,780	-7,478	-4,017	-3,918	-3,827	-3,004	-3,005
Share Based Compensation	45.9%	2,162	1,482	1,441	1,354	1,610	1,757	1,739	1,107	844	782	733	656	599	592	468	619	134	103	49.00	44.00	48.00
Cashflow From Investing	433.1%	7,857	-2,359	-14,979	-561	5,315	-64,870	-29.00	-14.00	-93.00	-1,083	-517	-625	-1,160	-1,101	-589	-77.00	-8.00	-80.00	-10.00	-69.00	-52.00
Cashflow From Financing	-54.3%	8,644	18,920	-418	47,185	4.00	-	-236	96,487	6.00	-4.00	-84.00	185	262	7.00	-675	58,907	29,464	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

LYRA Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Collaboration revenue	$ 532	$ 410
Operating expenses:
Research and development	18,238	12,596
General and administrative	5,818	5,127
Total operating expenses	24,056	17,723
Loss from operations	(23,524)	(17,313)
Other income:
Interest income	1,086	1,072
Total other income	1,086	1,072
Loss before income tax expense	(22,438)	(16,241)
Income tax expense	(14)	(14)
Net loss	(22,452)	(16,255)
Unrealized holding loss on short-term investments, net of tax	(8)	(22)
Comprehensive loss	$ (22,460)	$ (16,277)
Net loss per share attributable to common stockholders- basic	$ (0.35)	$ (0.44)
Net loss per share attributable to common stockholders- diluted	$ (0.35)	$ (0.44)
Weighted-average common shares outstanding-basic	64,011,360	36,832,747
Weighted-average common shares outstanding-diluted	64,011,360	36,832,747

LYRA Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 15,799	$ 22,353
Short-term investments	71,319	80,400
Prepaid expenses and other current assets	2,325	2,068
Total current assets	89,443	104,821
Property and equipment, net	3,783	2,043
Operating lease right-of-use assets	45,626	33,233
Restricted cash	1,992	1,392
Other assets	683	1,111
Total assets	141,527	142,600
Current liabilities:
Accounts payable	2,844	3,131
Accrued expenses and other current liabilities	10,057	9,374
Operating lease liabilities	4,504	5,434
Deferred revenue	1,319	1,658
Total current liabilities	18,724	19,597
Operating lease liabilities, net of current portion	33,356	21,447
Deferred revenue, net of current portion	11,943	12,136
Total liabilities	64,023	53,180
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023
Common stock, $0.001 par value; 200,000,000 shares authorized at March 31, 2024 and December 31, 2023; 60,964,775 and 57,214,550 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	61	57
Additional paid-in capital	411,225	400,685
Accumulated other comprehensive income, net of tax	25	33
Accumulated deficit	(333,807)	(311,355)
Total stockholders’ equity	77,504	89,420
Total liabilities and stockholders’ equity	$ 141,527	$ 142,600

About Lyra Therapeutics Inc

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

CEO	Dr. Maria Palasis Ph.D.
WEBSITE	https://lyratherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	73

Lyra Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Lyra Therapeutics Inc? What does LYRA stand for in stocks?

LYRA is the stock ticker symbol of Lyra Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Lyra Therapeutics Inc (LYRA)?

As of Fri May 17 2024, market cap of Lyra Therapeutics Inc is 23.17 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LYRA stock?

You can check LYRA's fair value in chart for subscribers.

What is the fair value of LYRA stock?

You can check LYRA's fair value in chart for subscribers. The fair value of Lyra Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Lyra Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LYRA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Lyra Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether LYRA is over valued or under valued. Whether Lyra Therapeutics Inc is cheap or expensive depends on the assumptions which impact Lyra Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LYRA.

What is Lyra Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, LYRA's PE ratio (Price to Earnings) is -0.34 and Price to Sales (PS) ratio is 13.79. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LYRA PE ratio will change depending on the future growth rate expectations of investors.